E-ISSN 2218-6050 | ISSN 2226-4485
 

Review Article


Polysulfated glycosaminoglycan as a treatment for osteoarthritis in veterinary medicine: Summary of the pharmacological, laboratory, and clinical data

Gary W. White.


Abstract
Polysulfated glycosaminoglycan (PSGAG) is an antiarthritic drug that has been used in veterinary medicine for many years. PSGAG is rapidly distributed to diseased joint tissue after intraarticular or intramuscular administration, as shown in pharmacological studies conducted on a variety of animal species. In diseased joint tissue, PSGAG stimulates: 1) its own incorporation into the cartilage matrix, 2) inhibition of catabolic enzymes, 3) anabolic effects in the synovial and cartilage tissue, and 4) anti-inflammatory effects. Laboratory and clinical studies in humans, rabbits, horses, and dogs have shown reduced severity of clinical signs and beneficial biochemical and morphological effects in inflamed or damaged joints. The drug has minimal side effects and adverse reactions in horses and dogs. Due to the above findings, PSGAG has been classified as a disease modifying osteoarthritis drug (DMOAD), and the drug remains a popular treatment for synovial inflammation and osteoarthritis in horses and dogs. Herein, we review the experimental and clinical evidence that led PSGAG to its classification as a DMOAD.

Key words: Polysulfated glycosaminoglycan; Osteoarthritis; Cartilage; Veterinary; Horse and dog.


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Gary W. White
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Gary W. White. Polysulfated glycosaminoglycan as a treatment for osteoarthritis in veterinary medicine: Summary of the pharmacological, laboratory, and clinical data. Open Vet. J.. 2025; 15(9): 4007-4023. doi:10.5455/OVJ.2025.v15.i9.6


Web Style

Gary W. White. Polysulfated glycosaminoglycan as a treatment for osteoarthritis in veterinary medicine: Summary of the pharmacological, laboratory, and clinical data. https://www.openveterinaryjournal.com/?mno=251210 [Access: October 06, 2025]. doi:10.5455/OVJ.2025.v15.i9.6


AMA (American Medical Association) Style

Gary W. White. Polysulfated glycosaminoglycan as a treatment for osteoarthritis in veterinary medicine: Summary of the pharmacological, laboratory, and clinical data. Open Vet. J.. 2025; 15(9): 4007-4023. doi:10.5455/OVJ.2025.v15.i9.6



Vancouver/ICMJE Style

Gary W. White. Polysulfated glycosaminoglycan as a treatment for osteoarthritis in veterinary medicine: Summary of the pharmacological, laboratory, and clinical data. Open Vet. J.. (2025), [cited October 06, 2025]; 15(9): 4007-4023. doi:10.5455/OVJ.2025.v15.i9.6



Harvard Style

Gary W. White (2025) Polysulfated glycosaminoglycan as a treatment for osteoarthritis in veterinary medicine: Summary of the pharmacological, laboratory, and clinical data. Open Vet. J., 15 (9), 4007-4023. doi:10.5455/OVJ.2025.v15.i9.6



Turabian Style

Gary W. White. 2025. Polysulfated glycosaminoglycan as a treatment for osteoarthritis in veterinary medicine: Summary of the pharmacological, laboratory, and clinical data. Open Veterinary Journal, 15 (9), 4007-4023. doi:10.5455/OVJ.2025.v15.i9.6



Chicago Style

Gary W. White. "Polysulfated glycosaminoglycan as a treatment for osteoarthritis in veterinary medicine: Summary of the pharmacological, laboratory, and clinical data." Open Veterinary Journal 15 (2025), 4007-4023. doi:10.5455/OVJ.2025.v15.i9.6



MLA (The Modern Language Association) Style

Gary W. White. "Polysulfated glycosaminoglycan as a treatment for osteoarthritis in veterinary medicine: Summary of the pharmacological, laboratory, and clinical data." Open Veterinary Journal 15.9 (2025), 4007-4023. Print. doi:10.5455/OVJ.2025.v15.i9.6



APA (American Psychological Association) Style

Gary W. White (2025) Polysulfated glycosaminoglycan as a treatment for osteoarthritis in veterinary medicine: Summary of the pharmacological, laboratory, and clinical data. Open Veterinary Journal, 15 (9), 4007-4023. doi:10.5455/OVJ.2025.v15.i9.6